Introduction
Infectious diseases represent one of the most frequent causes of death and the leading cause of disability-adjusted life years worldwide [1] (http://www.who.int/mediacentre/ factsheets/fs310_2008.pdf). Although the past decades have been marked by declining infectious disease-associated mortality, particularly in middle-and high-income countries, substantial year-to-year variation as well as the advent of (re)emerging infections underlines the dynamic nature of infectious diseases and the need for preparedness to address them [2, 3] .
The German Federal Ministry of Health reported that over 40,000 patients died from infections in 2006 and the number of deaths due to infection rose by 14% in the period between 2002 and 2006 [4] . Despite the many causes for this increase in mortality, the increasing number of bacterial infections caused by resistant pathogens during the last two decades presents one of the greatest challenges to medicine [5, 6] .
The introduction of new classes of antibiotics represents an important contribution to limiting the spread of resistant bacteria [7, 8] . Tigecycline, introduced in Germany in May 2006, is the first semi-synthetic glycylcycline antibiotic with in vitro activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms [9, 10] . The broad spectrum of activity includes multidrug-resistant (MDR) pathogens, such as methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae members and so-called "atypical" bacteria [11, 12] . Although structurally related to tetracyclines, the bacteriostatic effect of tigecycline is not impaired by the two main mechanisms leading to tetracycline resistance, i.e. ribosomal protection and tetracycline-specific efflux pumps [13] . Some taxa, such as Proteus, Providencia, Morganella, Burkholderia cepacia and Pseudomonas aeruginosa, however, show intrinsic reduced susceptibility to tigecycline [14, 15] . Rarely, resistance to tigecycline has also been observed in species that are usually susceptible, such as Klebsiella pneumonia and Escherichia coli [16] [17] [18] .
In two previous resistance surveillance surveys conducted throughout Germany (German Tigecycline Evaluation Surveillance Trial, G-TEST I and II, performed in 2005 and 2007, respectively), the susceptibility of over 2,500 bacterial isolates, each collected one year prior to and one year after the introduction of the new compound, was tested against tigecycline and comparators [19, 20] Only first isolates from the following sources were accepted for inclusion: peritoneal cavity, respiratory tract, blood, wounds and urine (<10% of the isolates). Coagulasenegative staphylococci (CoNS) were only included if they were recovered from at least two blood samples.
Identification of the pathogens was performed using standard laboratory methods. The bacterial strains were then kept at −70°C and sent to a central laboratory (Antiinfectives Intelligence, Rheinbach, Germany) for susceptibility testing at the end of the collection period.
Susceptibility testing
Minimal inhibitory concentrations (MICs) were determined using the microdilution broth method according to the standard ISO 20776-1:2006 [21] . The test medium was Mueller-Hinton II broth (Becton Dickinson GmbH, Heidelberg, Germany). Testing of the streptococci was performed using 3% lysed horse blood (Oxoid GmbH, Wesel, Germany). BBL™ Haemophilus test medium (Becton Dickinson GmbH, Heidelberg, Germany) was used to determine the susceptibility of H. influenzae. During the test period, reference strains were included in the susceptibility tests in the reference laboratory at least four times.
For Gram-positive bacteria, susceptibility to the following antibacterial agents was tested: amoxicillin/clavulanic acid, cefuroxime, doxycycline, gentamicin, imipenem, linezolid, moxifloxacin, oxacillin, penicillin G, piperacillin/ tazobactam, tigecycline and vancomycin. For Gramnegative bacteria, amoxicillin/clavulanic acid, cefepime, cefotaxime, ceftazidime, ciprofloxacin, doxycycline, ertapenem, gentamicin, imipenem, moxifloxacin, piperacillin/ tazobactam and tigecycline were included.
Isolates were defined as susceptible or resistant to antimicrobial agents in accordance with the species-related clinical breakpoints approved by the European Committee on Antimicrobial Susceptibility Testing (EUCAST, version 1.1), if available [22] . MICs of gentamicin for enterococci (high-level resistance) were interpreted by the cut-off values given by the Clinical Laboratory Standards Institute (CLSI) [23] . Isolates of E. coli and Klebsiella spp. were tested for ESBL production according to the broth dilution procedure described by the CLSI [24] .
Comparison of MDR versus non-MDR organisms
To compare the activity of tigecycline against the subset of MDR (i.e. in this study: imipenem-non-susceptible members of the A. baumannii group, cefotaxime-non-susceptible E. cloacae and S. marcescens, ESBL-positive E. coli, K. oxytoca and K. pneumoniae, MRSA and vancomycinresistant E. faecalis and E. faecium) versus corresponding non-MDR organisms of the included species, a total of 4,988 consecutively collected isolates from all three collection periods (April to August 2005; n=1,673; May to September 2007, n=1,649; April to September 2009, n= 1,666) were analysed. The numbers of isolates of the various species were as follows: A. baumannii group (n= 391), E. cloacae (n=681), E. coli (n=889), K. oxytoca (n= 305), K. pneumoniae (n=558), S. marcescens (n=370), S. aureus (n=910), as well as enterococcal isolates (n=884).
Results
Bacterial isolates, type of specimens and patients A total of 2,741 clinical isolates were collected by the 15 participating centres in 2009, with the number of strains per centre varying between 131 and 199. Sixty-seven percent and 33% of the isolates were obtained from patients on general wards and intensive care units, respectively. More than 60% of these patients were male. The age of the patients ranged from <1 to 98 years (median: 56 years).
The majority of isolates were derived from respiratory tract specimens (n=880, 32.1%), followed by wound specimens (n = 841, 30.7%), blood cultures (n = 607, 22.1%) and specimens of the peritoneal cavity (n=228, 8.3%).
Fifty-one percent and 30% of the infections were hospital-acquired and community-acquired, respectively. The acquisition of the infection was unknown for 19% of the patients. Ninety-one of 153 (59.5%) MRSA strains were associated with hospital-acquired and 32/153 (20.9%) with community-acquired infections, but 30/153 (19.6%) isolates could not be assigned to hospital-acquired or community-acquired infections. As for MRSA, ESBLproducing E. coli and Klebsiella isolates were predominantly associated with hospital-acquired infections (E. coli 59%, K. oxytoca 81.3%, K. pneumoniae 70.8%).
Susceptibility of the clinical isolates in comparison to previous G-TEST trials
The susceptibility data are shown in Table 1 (overview) and Online Resources 1 and 2 containing the MIC 50 and MIC 90 values, as well as the susceptibility and resistance rates. In addition, to demonstrate the trend of resistance, the results of the two previous trials (G-TEST I and II) are provided for comparison. The MIC values obtained for the reference strains corresponded well to the suggested concentration ranges given in the ISO 20776-1 document, as far as available.
Gram-positive bacteria As already observed in previous G-TEST studies, tigecycline demonstrated very good activity against S. aureus, with nearly identical activity against MSSA and MRSA isolates. In contrast, the susceptibility rates of moxifloxacin were 91.8% and only 2.0% for MSSA and MRSA, respectively. With regard to CoNS, only one strain (0.7%) of S. epidermidis was tigecycline-resistant (MIC 1 mg/L, which is one dilution above the upper breakpoint). As in previous studies, all staphylococcal strains tested were susceptible to vancomycin and linezolid. Against both E. faecalis and E. faecium, tigecycline remained the most active compound. Of the 298 enterococci tested, 279 and 17 isolates were inhibited by 0.125 mg/L and 0.25 mg/L of tigecycline, respectively. One strain of E. faecium had a tigecycline MIC of 0.5 mg/L (classified as intermediate) and one strain of E. faecalis had an MIC of 2 mg/L (classified as resistant). The MIC 90 of linezolid was 2 mg/L for both species, while the MIC 90 of vancomycin was 2 mg/L for E. faecalis and ≥32 mg/L for E. faecium. The percentage of vancomycin-resistant strains among E. faecium isolates (11.9%) was comparable to that found in G-TEST I (11.0%), but was lower than the rate found in G-TEST II (18.3%). In contrast, high-level resistance to gentamicin in both species increased from approximately 40% in G-TEST I and G-TEST II to about 50% in the present study. As in the previous studies, tigecycline demonstrated very good activity against the three streptococcal species tested, with all isolates inhibited by 0.125 mg/L of tigecycline, including those with reduced susceptibility to doxycycline and/or penicillin.
Gram-negative bacteria As in the G-TEST I and II trials, tigecycline demonstrated very good in vitro activity against E. coli. While 296 of the 297 isolates tested were tigecycline-susceptible, the remaining isolate was resistant (MIC 4 mg/L). Of interest, 25.3% of the tested E. coli isolates were resistant to ciprofloxacin and moxifloxacin. The percentage of isolates producing an ESBL phenotype was 13.1% (39/297) in this trial compared to 5.7% (17/300) in G-TEST I and 12% (35/292) in G-TEST II. The resistance rates of K. oxytoca and K. pneumoniae for tigecycline were comparable to those found in the previous studies, while those of E. cloacae and S. marcescens increased, from 6.9% in G-TEST I and 6.3% in G-TEST II to 10.2% in G-TEST III and from 3.4% in G-TEST I and 2.4% in G-TEST II to 7.0% in G-TEST III, respectively. values (mg/L) for ESBL-producing E. coli (0.25/0.5), K. oxytoca (0.5/1) and K. pneumoniae (1/2) and cefotaxime-non-susceptible S. marcescens isolates (1/2) that were identical or within one doubling dilution compared to the susceptible and ESBL-negative subpopulations. The MIC 50 /MIC 90 values of tigecycline for cefotaxime-susceptible and cefotaxime-non-susceptible E. cloacae isolates were 0.5/1 and 0.5/4, respectively. For bacteria of the A. baumannii group, the activity of tigecycline against imipenem-non-susceptible isolates (1/2) was 4-fold higher than for imipenem-susceptible isolates (0.25/0.5).
Discussion
The present study, conducted three years following the introduction of tigecycline for clinical use in Germany, evaluated the susceptibility of German hospital bacterial isolates to tigecycline in comparison to other drugs. Overall, the susceptibility to tigecycline did not change compared to pre-marketing baseline values or those evaluated one year after the introduction of tigecycline [19, 20] . Except for P. aeruginosa, the glycylcycline demonstrated very good in vitro activity against all species tested, including MDR pathogens such as MRSA and VRE. Similar trends were recently observed in two other large surveillance studies, which included regions with increasing rates of MDR pathogens [25, 26] . Of particular interest, tigecycline exhibited very good in vitro activity against ESBL-and/or AmpC-producing Enterobacteriaceae. On the whole, the activity profile of tigecycline was not notably affected by organisms resistant to other drug classes except by A. baumannii group isolates with decreased susceptibility to carbapenems. However, tigecycline had the lowest MIC 90 of all study drugs for imipenem-nonsusceptible A. baumannii group isolates. In a global surveillance study of Acinetobacter from blood samples collected between 2004 and 2008, an increase in the MIC 90 value of tigecycline was observed [27] .
Except for two E. faecium isolates, one each recovered in G-TEST I and G-TEST III, no further linezolid-resistant Gram-positive pathogens were observed in the three G-TEST studies. Although 99.55% of the tested 2,006 isolates in the U.S. LEADER program remained susceptible to linezolid [28] , the reported linezolid-resistant S. aureus (n=1), CoNS (n=13), E. faecalis (n=3), and E. faecium (n=10) isolates should not be underestimated. Besides the most common mechanism of linezolid resistance in S. aureus reported to date, mutation G2576T in the domain V of 23S rRNA, in particular, the cfr mutation, give cause for concern. This novel multidrug resistance phenotype mediated by the Cfr rRNA methyltransferase cause resistance not only to oxazolidinones, but also to phenicols, lincosamides, pleuromutilins and streptogramin A, and is plasmidencoded, thus, conferring transferable oxazolidinone resistance [29] . Thus, not unexpectedly, first clinical outbreaks of linezolid-resistant MRSA and S. epidermidis clones have recently been noted in Spain and Ohio, USA [30, 31] .
In contrast, susceptibility to β-lactams or fluoroquinolones decreased in members of the family Enterobacteriaceae and in non-fermenting Gram-negative bacteria between 2005 and 2009. Since fluoroquinolones have become some of the most frequently prescribed antimicrobial agents worldwide, decreasing susceptibilities of Gramnegative rods towards this antibiotic class have been observed also in other parts of the world in the past several years [32] [33] [34] . Also, a substantial rise in the rate of enterococci with high-level resistance to gentamicin (HLGR), which reached about 50% in 2009, was observed. HLGR in enterococci has also increased in Greece within the past decade [35] . In contrast, in four north European countries (Denmark, Finland, Norway and Sweden), HLGR occurred in 11-25% of E. faecium and 6-20% of E. faecalis isolates, with a significantly higher HLGR rate among E. faecalis from hospitalised patients [36] . The number of vancomycin-resistant E. faecium strains varied between 11% and 18%, while vancomycin-resistant E. faecalis strains were not detected in the three G-TEST collection periods. However, decreased susceptibility to vancomycin was found among 2.0% and 0.6% of the E. faecium and E. faecalis isolates, respectively, in the multicentre study performed in the four Nordic countries mentioned above [36] .
In summary, in this third nationwide surveillance study on tigecycline susceptibility in Germany, tigecycline retained its very good in vitro activity against aerobic Gram-positive and Gram-negative bacteria. Therefore, tigecycline still holds promise as a suitable option most notably for calculated antibiotic treatment in those clinical situations in which multi-resistant organisms are suspected.
